Provided by Tiger Fintech (Singapore) Pte. Ltd.

Entera Bio Ltd.

1.92
+0.03001.59%
Volume:10.90K
Turnover:20.71K
Market Cap:87.27M
PE:-7.48
High:1.94
Open:1.89
Low:1.87
Close:1.89
Loading ...

Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting

GlobeNewswire
·
26 Jun

Entera Bio Files $100 Million Mixed Shelf

MT Newswires Live
·
31 May

Entera Bio files $100M mixed securities shelf

TIPRANKS
·
31 May

Entera Bio Ltd. Files Initial Statement of Beneficial Ownership for Chief Business Officer Gautam Leslie Velka

Reuters
·
21 May

Entera Bio Q1 EPS $(0.06) Beats $(0.07) Estimate, Sales $42.00K

Benzinga
·
10 May

Press Release: Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

Dow Jones
·
10 May

Entera Bio Ltd expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
06 May

Entera Bio announces highlights from presentation at WCO-IFO-ESCEO on EB613

TIPRANKS
·
15 Apr

Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO

GlobeNewswire
·
15 Apr

Entera Bio Ltd reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
02 Apr

Entera Bio Ltd expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
31 Mar

Entera Bio FY 2024 GAAP EPS $(0.25), Sales $181.000K Beat $139.000K Estimate

Benzinga
·
29 Mar

Press Release: Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

Dow Jones
·
29 Mar

Entera Bio Ltd expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
21 Mar

Entera Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Mar

Opko Health, Entera Bio to Collaborate on Tablet for Obesity, Metabolic and Fibrotic Disorders

Dow Jones
·
17 Mar

OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity

MT Newswires Live
·
17 Mar

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

GlobeNewswire
·
17 Mar

Entera Bio Ltd expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
17 Mar

Entera Bio Ltd expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
10 Mar